Literature DB >> 22082308

The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.

C Huang1, R Huang, W Chang, T Jiang, K Huang, J Cao, X Sun, Z Qiu.   

Abstract

Signal transducers and activators of transcription 3 (STAT3) is a central cytoplasmic transcription factor and regulates a number of pathways important in tumorigenesis including cell cycle progression, apoptosis, tumor angiogenesis, invasion and metastasis.This study aims to investigate the expression of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma and their relations to the clinicopathological features, tumor angiogenesis and prognosis. In the present study, the expression of pSTAT3, VEGF and VEGF-C and microvascular density (MVD) were examined via immunohistochemistry. The clinicopathological information was collected and patients were regularly followed up. The relationship between the parameters and the clinicopathological features were analyzed, and the univariate and multivariate prognostic factors were also analyzed. The expression of pSTAT3 in tumor tissues was significantly higher in contrast to that in normal tissues, and pSTAT3 was related to VEGF and VEGF-C expression, MVD, tumor size, lymphogenous status and TNM staging (P<0.05). Survival analysis suggested that tumor size, TNM staging, pSTAT3 and VEGF expression were risk factors of prognosis, but no independent factors were found. We concluded that pSTAT3, which was a risk factor of prognosis, was abnormally expressed in pancreatic adenocarcinoma and related to tumor size, TNM staging and lymphatic metastasis. pSTAT3 may promote tumor angiogenesis via up-regulating VEGF on protein and even gene levels, and enhance the early lymphatic metastasis through VEGF-C. Better understanding of STAT3 signaling pathways in angiogenesis may contribute to the development of novel therapeutic strategies in angiogenesis and metastasis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22082308     DOI: 10.4149/neo_2012_007

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  20 in total

1.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Jiawei Du; Keping Xie
Journal:  Biochim Biophys Acta       Date:  2014-01-11

2.  STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell.

Authors:  Jingyu Deng; Jingli Cui; Nan Jiang; Rupeng Zhang; Li Zhang; Xishan Hao; Han Liang
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

3.  Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.

Authors:  Ravi Kasiappan; Indira Jutooru; Keshav Karki; Erik Hedrick; Stephen Safe
Journal:  J Biol Chem       Date:  2016-11-15       Impact factor: 5.157

4.  Expression of p-STAT3 and vascular endothelial growth factor in MNNG-induced precancerous lesions and gastric tumors in rats.

Authors:  Xiao-Yan Wang; Lou-Lei Wang; Xuan Zheng; Li-Na Meng; Bin Lyu; Hai-Feng Jin
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

5.  Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer.

Authors:  L I Yan; L I Li; Qinghuai Li; Wang DI; Wei Shen; Linlei Zhang; Hao Guo
Journal:  Exp Ther Med       Date:  2015-04-07       Impact factor: 2.447

6.  Active Stat3 and Her-2 as combined survival predictors show superiority to TNM staging system for postoperative patients with gastric cancer.

Authors:  Ke Sun; Meng Qing Xu; Hai Jun Zhang; Dan Dan Zhang; Wen Yue; Miao Miao Ma; Lin Tao; Wen Jie Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 4.060

7.  The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.

Authors:  Yinxu Zhang; Xiaomei Liu; Junhua Zhang; Leiyu Li; Chunying Liu
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

Review 8.  Genetically engineered mouse models of pancreatic adenocarcinoma.

Authors:  Carmen Guerra; Mariano Barbacid
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.

Authors:  Joseph Markowitz; Taylor R Brooks; Megan C Duggan; Bonnie K Paul; Xueliang Pan; Lai Wei; Zachary Abrams; Eric Luedke; Gregory B Lesinski; Bethany Mundy-Bosse; Tanios Bekaii-Saab; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2014-10-11       Impact factor: 6.968

10.  Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.

Authors:  Thomas A Mace; Zeenath Ameen; Amy Collins; Sylwia Wojcik; Markus Mair; Gregory S Young; James R Fuchs; Tim D Eubank; Wendy L Frankel; Tanios Bekaii-Saab; Mark Bloomston; Gregory B Lesinski
Journal:  Cancer Res       Date:  2013-03-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.